Publications by authors named "Jun Horiguchi"

Claim this Profile
M
Molecular and Biological Features of Invasive Lobular Carcinoma: Toward New Treatment Strategies.
Nanaka Ozawa, Erina Takeyama, Honoka Sakai, Ayaka Katayama, Mai Onishi, Jun Horiguchi

Ann Surg Oncol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic drug monitoring of docetaxel administered for breast cancer in a patient receiving rifampicin and clarithromycin to treat nontuberculous mycobacteriosis: A case report.
Hideaki Yashima, Takuya Araki, Yuya Ishikawa, Sohei Ohshima, Daisuke Nagano, Jun Horiguchi

Mol Clin Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current status and prospects of artificial intelligence in breast cancer pathology: convolutional neural networks to prospective Vision Transformers.
Ayaka Katayama, Yuki Aoki, Yukako Watanabe, Jun Horiguchi, Emad A Rakha

Int J Clin Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current status and prospects of breast cancer imaging-based diagnosis using artificial intelligence.
Chikako Sekine, Jun Horiguchi

Int J Clin Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Significance of FAM83G in Breast Cancer: Association With Triple-negative Subtype and Prognosis.
Takako Ikeda, Chikako Kanno Honda, Sasagu Kurozumi, Takehiko Yokobori, Ayaka Katayama, Jun Horiguchi

Anticancer Res· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Utility of human epidermal growth factor 2 heterogeneity as a prognostic factor in triple-negative breast cancer.
Eriko Narusawa, Sasagu Kurozumi, Ayaka Katayama, Yukio Koibuchi, Akira Ogawa, Jun Horiguchi

Med Mol Morphol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Significance of MUC1 and β-Catenin Localization in Mucinous Carcinoma of the Breast.
Kei Sugawara-Komatsu, Takaaki Fujii, Sasagu Kurozumi, Hitoshi Ishikawa, Ayaka Katayama, Jun Horiguchi

Anticancer Res· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer-associated fibroblast spatial heterogeneity and expression in the tumor microenvironment modulate TGF-β activity and CD8 T-cell infiltration in breast cancer.
Chikako Kanno Honda, Sasagu Kurozumi, Takaaki Fujii, Didier Pourquier, Lakhdar Khellaf, Jun Horiguchi

Theranostics· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of MicroRNAs Associated with Histological Grade in Early-Stage Invasive Breast Cancer.
Sasagu Kurozumi, Naohiko Seki, Eriko Narusawa, Chikako Honda, Shoko Tokuda, Jun Horiguchi

Int J Mol Sci· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter, double-blind, randomized, controlled study of patients with treatment-resistant schizophrenia treated with yokukansan for 12 weeks.
Jun Horiguchi, Rei Wake, Kenta Murotani, Haruo Seno, Tsuyoshi Miyaoka

PCN Rep· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fibrocystic breast disease with pleomorphic calcifications and segmental distribution: A case report.
Kuo JiueLan, Chikako Sekine, Sasagu Kurozumi, Ryosuke Matsuoka, Mina Komuta, Jun Horiguchi

Radiol Case Rep· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized Controlled Phase 2 Study of Neoadjuvant Eribulin Versus Paclitaxel in Women with Operable Breast Cancer: The JONIE-3 Study.
Kazutaka Narui, Daishu Miura, Yoshie Hasegawa, Akihiko Tachibana, Jun Horiguchi

Clin Breast Cancer· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Strontium-89 plus zoledronic acid versus zoledronic acid for patients with painful bone metastatic breast cancer.
Kimito Yamada, Hiroshi Kaise, Tetsuya Taguchi, Jun Horiguchi, Shintaro Takao

J Bone Miner Metab· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of valbenazine in Japanese patients with tardive dyskinesia: A multicenter, randomized, double-blind, placebo-controlled study (J-KINECT).
Jun Horiguchi, Koichiro Watanabe, Kazuoki Kondo, Atsushi Iwatake, Hajime Sakamoto

Psychiatry Clin Neurosci· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Urinary biopyrrins and free immunoglobin light chains are biomarker candidates for screening at-risk mental state in adolescents.
Rei Wake, Tomoko Araki, Michiyo Fukushima, Hiroyuki Matsuda, Takuji Inagaki, Jun Horiguchi

Early Interv Psychiatry· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of L-type amino acid transporter 1 (LAT1) with the immune system and prognosis in invasive breast cancer.
Sasagu Kurozumi, Kyoichi Kaira, Hiroshi Matsumoto, Masafumi Kurosumi, Takehiko Yokobori, Jun Horiguchi

Sci Rep· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic value of tumor-infiltrating lymphocytes in estrogen receptor-positive and human epidermal growth factor receptor 2-negative breast cancer.
Chikako Honda, Sasagu Kurozumi, Ayaka Katayama, Bishoy Hanna-Khalil, Kei Masuda, Jun Horiguchi

Mol Clin Oncol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low Serum Levels of Fibroblast Growth Factor 2 in Gunn Rats: A Hyperbilirubinemia Animal Model of Schizophrenic Symptoms.
Maiko Hayashida, Sadayuki Hashioka, Kenji Hayashida, Shoko Miura, Keiko Tsuchie, Jun Horiguchi

CNS Neurol Disord Drug Targets· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinicopathological utility of human epidermal growth factor receptor 2 (HER2)-heterogeneity for next-generation treatments of triple-negative breast cancer.
Sasagu Kurozumi, Ayaka Katayama, Ken Shirabe, Jun Horiguchi, Emad A Rakha

Oncotarget· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Implications of Topoisomerase (TOP1 and TOP2α) Expression in Patients With Breast Cancer.
Misato Ogino, Takaaki Fujii, Yuko Nakazawa, Toru Higuchi, Yukio Koibuchi, Jun Horiguchi

In Vivo· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of Ninjin'yoeito (NYT) in treatment-resistant schizophrenia: Open-Label Study.
Tsuyoshi Miyaoka, Rei Wake, Tomoko Araki, Ken Inoue, Jun Horiguchi

Asian J Psychiatr· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of sequential S-1 and cyclophosphamide therapy in patients with metastatic breast cancer.
Keiko Yanai, Takaaki Fujii, Jun Horiguchi, Yuko Nakazawa, Sasagu Kurozumi

BMC Cancer· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The pathological complete response and secreted protein acidic and rich in cysteine expression in patients with breast cancer receiving neoadjuvant nab-paclitaxel chemotherapy.
Yuko Nakazawa, Seshiru Nakazawa, Sasagu Kurozumi, Misato Ogino, Yukio Koibuchi, Jun Horiguchi

Oncol Lett· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RNA-sequence-based microRNA expression signature in breast cancer: tumor-suppressive miR-101-5p regulates molecular pathogenesis.
Hiroko Toda, Naohiko Seki, Sasagu Kurozumi, Yoshiaki Shinden, Yasutaka Yamada, Jun Horiguchi

Mol Oncol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinicopathological values of PD-L1 expression in HER2-positive breast cancer.
Sasagu Kurozumi, Kenichi Inoue, Hiroshi Matsumoto, Takaaki Fujii, Jun Horiguchi

Sci Rep· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis